A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.
A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.
